The amyotrophic lateral sclerosis center: A model of multidisciplinary management

Critical Reviews in Physical and Rehabilitation Medicine

Volumn 15, Issue 1, 2003, Pages 21-40

  Han, Jay J ^a   Carter, Gregory T ^a   Hecht, Thomas W ^a   Schuman, Nancy E ^a,b   Weiss, Michael D ^a   Krivickas, Lisa S ^c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c HARVARD UNIVERSITY   (United States)

Author keywords

Amyotrophic lateral sclerosis; Bulbar palsy; Lou Gehrig's disease; Muscular atrophy; Neuron disorder

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ASCORBIC ACID; BETA CAROTENE; CREATINE; RILUZOLE; UBIQUINONE;

AMYOTROPHIC LATERAL SCLEROSIS; ASTHENIA; DIARRHEA; DIETITIAN; GASTROINTESTINAL SYMPTOM; HUMAN; LIVER TOXICITY; MEDICAL SPECIALIST; MOTOR NEURON DISEASE; NAUSEA; OCCUPATIONAL THERAPIST; PHYSIOTHERAPIST; PRIORITY JOURNAL; PSYCHOLOGIST; REVIEW; SIDE EFFECT; SOCIAL WORKER;

EID: 0038193858     PISSN: 08962960     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevPhysRehabilMed.v15.i1.20     Document Type: Review

References (85)

1. Siddique T, Deng H. Genetics of ALS. Hum Mol Genet 1996; 1465-1470.
2. Lyons TJ, Liu H, Goto JJ, et al. Mutations in copperzinc superoxide dismutase that cause amyotrophic lateral sclerosis alter the zinc binding site and the redux behavior of the protein. Proc Natl Acad Sci U S A 1996; 93(22):12240-12244.
3. Hosler BA, Brown RH. Copper/zinc superoxide dismutase mutations and free radical damage in amyotrophic lateral sclerosis. Adv Neurol 1995; 680:41-46.
4. Canu W, Billiard M, Baldy-Mouliner M. Fasting plasma and CSF amino acid levels in ALS. Acta Neurol Scand 1993; 88(1):51-55.
5. Plaitakis A, Constantakakis E. Altered metabolism of excitatory amino acids, N-acetyl-aspartate-glutamate in amyotrophic lateral sclerosis. Brain Res Bull 1993; 30:381-386.
6. Rothstein JD, Martin IJ, Kuncl RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med 1992; 326:1464-1468.
7. Rothstein JD, Van Kammen M, Levey AL, Martin LJ, Kuncl RW. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995; 38:73-84.
8. Nelson LM, Matkin C, Longstreth WT Jr, McGuire V. Population-based case-control study of amyotrophic lateral sclerosis in western Washington State. II. Diet. Am J Epidemiol 2000; 151(2):164-173.
9. Nelson LM, McGuire V, Longstreth WT Jr, Matkin C. Population-based case-control study of amyotrophic lateral sclerosis in western Washington State. I. Cigarette smoking and alcohol consumption. Am J Epidemiol 2000; 151(2):156-163.
10. Longstreth WT, Nelson LM, Koepsell TD, van Belle G. Hypotheses to explain the association between vigorous physical activity and amyotrophic lateral sclerosis. Med Hypotheses 1991; 34:144-148.
11. Scarmeas N, Shih T, Stern Y, Ottman R, Rowland LP. Premorbid weight, body mass, and varsity athletics in ALS. Neurology. 2002; 59(5):773-775.
12. Norris F, Sheperd R, Denys E, et al. Onset, natural history and outcome in idiopathic adult motor neuron disease. J Neurol Sci 1993; 118(1):48-55.
13. Pradas J, Finison L, Andres PL, Thornell B, Hollander D, Munsat TL. The natural history of amyotrophic lateral sclerosis and the use of natural history controls in therapeutic trials. Neurology 1993; 43(4):751-755.
14. Ringel SP, Murphy JR, Alderson MK, et al. The natural history of amyotrophic lateral sclerosis. Neurology 1993; 43(7):1316-1322.
15. Chancellor AM, Warlow CP. Adult onset motor neuron disease: worldwide mortality, incidence, and distribution since 1950. J Neurol Neurosurg Psychiatry 1992; 55(12):1106-1115.
16. Neilson S, Robinson I, Alperovitch A. Rising amyotrophic lateral sclerosis mortality in France 1968-1990: increased life expectancy and inter-disease competition as an explanation. J Neurol 1994; 241(7):448-455.
17. Neilson S, Robinson I, Nymoen EH. Longitudinal analysis of amyotrophic lateral sclerosis mortality in Norway, 1966-1989: evidence for a susceptible subpopulation. J Neurol Sci 1994; 122(2):148-154.
18. Mitsumoto H, Chad DA, Pioro EP. Amyotrophic lateral sclerosis. Philadelphia: F. A. Davis, 1998.
19. Kasarskis EJ, Berryman S, Vanderleest JG, Schneider AR, McClain CJ. Nutritional status of patients with amyotrophic lateral sclerosis: relation to the proximity of death. Am J Clin Nutr 1996; 63:130-137.
20. Sharma KR, Miller RG. Electrical and mechanical properties of skeletal muscle underlying increased fatigue in patients with amyotrophic lateral sclerosis. Muscle Nerve 1996; 19:1391-1400.
21. Kothari MJ, Rutkove SJ, Logigian EL, Shefner JM. Coexistent entrapment neuropathies in patients with amyotrophic lateral sclerosis. Arch Phys Med Rehabil 1996; 77:1186-1188.
22. Okuda B, Kodama N, Kawabata K, Tachibana H, Sugita M. Corneomandibular reflex in ALS. Neurology 1999; 52:1699-1701.
23. Lambert E, Mulder D Electromyographic studies in amyotrophic lateral sclerosis. Mayo Clin Proc 1957; 332:441-446.
24. Lambert E. Electromyography in amyotrophic lateral sclerosis. In: Norris F, Kurland L, editors. Motor Neuron Disease. New York: Grune and Stratton, 1969: 135-153.
25. Cornblath DR, Kuncl RW, Mellits ED, et al. Nerve conduction studies in amyotrophic lateral sclerosis. Muscle Nerve 1992; 15:1111-1115.
26. Brooks B. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial Clinical Limit of Amyotrophic Lateral Sclerosis Workshop contributors. J Neuro Sci 1994; 124:96-107.
27. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. London: World Federation of Neurology Research Group on Motor Neuron Diseases, 1998.
28. Dumitru D. Central nervous system disorders. In: Dumitru D, editor. Electrodiagnostic Medicine. Philadelphia: Hanley and Belfus, 1995: 453-422.
29. de Carvalho M, Miranda PC, Luis ML, Ducla-Soares E. Cortical muscle representation in amyotrophic lateral sclerosis patients: changes with disease evolution. Muscle Nerve 1999; 22:1684-1692.
30. Dettmers CD, Fatepour D, Faust H, Jerusalem F. Sympathetic skin response abnormalities in amyotrophic lateral sclerosis. Muscle Nerve 1993; 16:930-934.
31. Desiato MT, Palmieri MG, Giacomini P, Scalise A, Arciprete F, Caramia MD. The effect of riluzole in amyotrophic lateral sclerosis: a study with cortical stimulation. J Neuro Sci 1999; 169:98-107.
32. Schulte-Mattler WJ, Muller T, Zierz S. Transcranial magnetic stimulation compared with upper motor neuron signs in patients with amyotrophic lateral sclerosis. J Neuro Sci 1999; 170:51-56.
33. Ziemann UM, Winter M, Reimers CD, Reimers K, Tergau F, Paulus W. Impaired motor cortex inhibition in patients with amyotrophic lateral sclerosis. Evidence from paired transcranial magnetic stimulation. Neurology 1998; 49(5):1292-1298.
34. Bensimon GL, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. New Engl J Med 1994; 330:585-591.
35. Lacomblez, L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996; 347:1425-1431.
36. Drory VE, Sidi I, Korczyn AD. Riluzole-induced pancreatitis. Neurology 1999; 52:892-893.
37. Poloni TE, Alimonti D, Montagna G, et al. Renal tubular impairment during riluzole therapy. Neurology 1999; 52:670.
38. Practice advisory on the treatment of amyotrophic lateral sclerosis with riluzole. Neurology 1997; 49:657-659.
39. Vyth A, Timmer GJ, Bossuyt TM, Louwerse ES, de Jong JM. Survival in patients with amyotrophic lateral sclerosis treated with an array of antioxidants. J Neuro Sci 1996; 139(suppl):99-103.
40. Klivenyi P, Ferrante RJ, Matthews RT, et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nature Med 1999; 5(3):347-350.
41. Tarnopolsky M, Martin J. Creatine monohydrate increases strength in patients with neuromuscular disease. Neurology 1999; 52:854-857.
42. Hultman E, Soderlund K, Timmons JA, Cederblad G, Greenhaff PL. Muscle creatine loading in men. J Appl Physiol 1996; 81:232-237.
43. Pritchard NR, Kaira PA. Renal dysfunction accompanying oral creatine supplements. Lancet 1998; 351:1252-1253.
44. Fowler WM, Carter GT, Kraft GH. Role of physiatry in the management of neuromuscular disease. In: Physical Medicine and Rehabilitation Clinics of North America. Philadelphia: W. B. Saunders, 1998: 1-8.
45. Francis K, Bach JR, DeLisa JA. Evaluation and rehabilitation of patients with adult motor neuron disease. Arch Phys Med Rehabil 1999; 80:951-963.
46. Aitkens SG, McCrory MA, Kilmer DD, Bernauer EM. Moderate resistance exercise program: its effects in slowly progressive neuromuscular disease. Arch Phys Med Rehabil 1993; 74(7):711-715.
47. Kilmer DD, McCrory MA, Wright NC, Aitkens SG, Bemauer EM. The effect of a high resistance exercise program in slowly progressive neuromuscular disease. Arch Phys Med Rehabil 1994; 75(5):560-563.
48. Kilmer DD. The role of exercise in neuromuscular disease. In: Physical Medicine and Rehabilitation Clinics of North America. Philadelphia: W. B. Saunders, 1998: 115-125.
49. Carter GT, Miller RG. Comprehensive management of amyotrophic lateral sclerosis. In: Physical Medicine and Rehabilitation Clinics of North America. Philadelphia: W. B. Saunders, 1998: 271-284.
50. Sharma KR, Kent-Braun JA, Majumdar S, et al. Physiology of fatigue in amyotrophic lateral sclerosis. Neurology 1995; 45(4):733-740.
51. Carter GT, Johnson ER, Bonekat HW, Lieberman JS. Laryngeal diversion in the treatment of intractable aspiration in motor neuron disease. Arch Phys Med Rehabil 1992; 73(7):680-682.
52. Miller RG, Rosenberg JA, Gelinas DF, et al. Practice parameter: the care of patients with amyotrophic lateral sclerosis (an evidence-base review). Muscle Nerve 1999; 22:1104-1118.
53. Langmore SE, Schatz MA, Olsen N. Fiberoptic endoscopic examination of swallowing safety: a new procedure. Dysphagia 1988; 2:216-219.
54. Krivickas LS. Pulmonary function and respiratory failure. In: Mitsumoto H, Chad DA, Pioro EP, editors. Amyotrophic Lateral Sclerosis. Philadelphia: F. A. Davis, 1998: 382-404.
55. Benditt JO. Management of pulmonary complications in neuromuscular disease. In: Physical Medicine and Rehabilitation Clinics of North America. Philadelphia: W. B. Saunders, 1998: 167-185.
56. Bach JR. Amyotrophic lateral sclerosis: communication status and survival with ventilatory support. Arch Phys Med Rehabil 1993; 72(6):343-349.
57. Bach JR. Amyotrophic lateral sclerosis: predictors for prolongation of life by noninvasive respiratory aids. Arch Phys Med Rehabil 1995; 76(9):828-832.
58. Bach JR. Amyotrophic lateral sclerosis. Prolongation of life by noninvasive respiratory aids. Chest 2002; 122:92-98.
59. Hanayama K, Ishikawa Y, Bach JR. Amyotrophic lateral sclerosis. Successful treatment of mucous plugging by mechanical insufflation-exsufflation. Am J Phys Med Rehabil 1997; 76:338-339.
60. Fields HL. Relief of unnecessary suffering. In: Fields HL, Liebeskind JC, editors. Pharmacologic Approaches to the Treatment of Chronic Pain: New Concepts and Critical Issues. Seattle, WA: International Association for the Study of Pain Press, 1994; 1-11.
61. Abresch RT, Seyden NK, Wineinger MA. Quality of life: issues for persons with neuromuscular diseases. In: Physical Medicine and Rehabilitation Clinics of North America. Philadelphia: W. B. Saunders, 1998: 233-248.
62. Carvalho M, Schwartz MS, Swash M. Involvement of the external anal sphincter in amyotrophic lateral sclerosis. Muscle Nerve 1995; 18:848-853.
63. Brown RH, Meininger V, Swash M, eds. Amyotrophic lateral sclerosis. London: Martin Duntz, 2000.
64. Pisano F, Miscio G, Mazzuero G, Lanfranchi P, Colombo R, Pinelli P. Decreased heart rate variability in amyotrophic lateral sclerosis. Muscle Nerve 1995; 18:1225-1231.
65. Hunter MD, Robinson IC, Neilson S. The functional and psychological status of patients with amyotrophic lateral sclerosis: some implications for rehabilitation. Disabil Rehabil 1993; 15(3):119-126.
66. Meininger V. Breaking bad news in amyotrophic lateral sclerosis. Pall Med 1993; 7(suppl 4):37-40.
67. Bernat JL. Ethical and legal issues in the management of amyotrophic lateral sclerosis. In: Belsh JM, Schiffman PL, editors. Amyotrophic Lateral Sclerosis: Diagnosis and Management for the Clinician. Armonk, NY: Futura, 1996: 357-372.
68. Carter GT, Butler LM, Abresch RT, Ugalde VO. Expanding the role of hospice in the care of amyotrophic lateral sclerosis. Am J Hosp Pall Care 1999; 16(6):707-710.
69. Ganzini L, Johnston WS, McFarland BH, Tolle SW, Lee MA. Attitudes of patients with amyotrophic lateral sclerosis and their caregivers toward assisted suicide. N Engl J Med 1998; 339(14):967-973.
70. Moore MK. Dying at home: a way of maintaining control for the person with ALS/MND. Pall Med 1993; 7(suppl 4):65-68.
71. Oppenheimer EA. Decision-making in the respiratory care of amyotrophic lateral sclerosis: should home mechanical ventilation be used? Pall Med 1993; 7(suppl 4):49-64.
72. Krivickas LS, Shockley L, Mitsumoto H. Homecare of patients with amyotrophic lateral sclerosis (ALS). J Neurol Sci 1997; 152(suppl 1):S82-S89.
73. Standards and Accreditation Committee Medical Guidelines Task Force. Medical guidelines for determining prognosis in selected non-cancer diseases. The National Hospice Organization, 1996.
74. Enck RE. Hospice: the next step. Am J Hosp Pall Care 1999; 16(2):436-437.
75. ALS CNTF Study Group. A double-blind placebocontrolled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology 1996; 46:1244-1249.
76. BDNF Study Group. A controlled trial of recombinant methionyl human BDNF in ALS. Neurology 1999; 52:1427-1433.
77. Miller RG, Petajan JH, Bryan WW, et al. A placebocontrolled trial of recombinant human ciliary neurotrophic factor in amyotrophic lateral sclerosis. Ann Neurol 1996; 39(2):256-260.
78. Lange DJ, Felice KJ, Festoff BW, et al. Recombinant human insulin-like growth factor-I in ALS: description of a double-blind, placebo-controlled study. Neurology 1996 47:S93-S95.
79. Borasio GD, Robberecht W, Leigh PN, et al. A placebo-controlled trial of insulin-like growth factor I in amyotrophic lateral sclerosis. Neurology 1998; 51:583-586.
80. Miller RG, Moore D, Young LA, et al. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 1996; 47:1383-1388.
81. Blin O, Azulay JP, Desnuelle C, et al. A controlled one-year trial of dextromethorphan in amyotrophic lateral sclerosis. Clin Neuropharm 1996; 19:189-192.
82. Gredal O, Werdelin L, Bak S, et al. A clinical trial of dextromethorphan in amyotrophic lateral sclerosis. Acta Neurol Scand 1997; 96:8-13.
83. Miller RG, Shepherd R, Dao H, et al. A controlled trial of nimodipine in amyotrophic lateral sclerosis. Neuromusc Dis 1996; 6:101-104.
84. Miller RG, Smith SA, Murphy JR, et al. A clinical trial of verapamil in amyotrophic lateral sclerosis. Muscle Nerve 1996; 19:511-515.
85. Italian ALS Study Group. Branched-chain amino acids and amyotrophic lateral sclerosis: a treatment failure? Neurology 1993; 43:2466-2470.